The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
The T1D Fund, an impact investment fund focused on type 1 diabetes solutions, has appointed Elizabeth Mily as CEO. Mily brings over 30 years of experience from roles at Bristol Myers Squibb, Goldman Sachs, and Barclays, where she specialized in corporate strategy and business development.
In her new role, Mily will guide the fund's resource deployment and expand strategic partnerships to build an ecosystem for new therapies. She will serve as the fund's lead public ambassador, working to increase awareness and investment in T1D research and innovation.
Prior to joining T1D Fund, Mily served as Executive Vice President of Strategy & Business Development at Bristol Myers Squibb, overseeing company strategy, external innovation, and business development. She currently serves on the Board of Solventum (NYSE: SOLV) and Ampersand Biomedicines.
Il T1D Fund, un fondo di investimento a impatto focalizzato sulle soluzioni per il diabete di tipo 1, ha nominato Elizabeth Mily come CEO. Mily porta con sé oltre 30 anni di esperienza in ruoli presso Bristol Myers Squibb, Goldman Sachs e Barclays, dove si è specializzata nella strategia aziendale e nello sviluppo commerciale.
Nella sua nuova posizione, Mily guiderà l'impiego delle risorse del fondo e ampliará le partnership strategiche per costruire un ecosistema per le nuove terapie. Inoltre, sarà la principale ambasciatrice pubblica del fondo, lavorando per aumentare la consapevolezza e gli investimenti nella ricerca e innovazione sul T1D.
Prima di unirsi al T1D Fund, Mily ha ricoperto il ruolo di Vicepresidente Esecutivo di Strategia e Sviluppo Aziendale presso Bristol Myers Squibb, supervisionando la strategia aziendale, l'innovazione esterna e lo sviluppo commerciale. Attualmente fa parte del Consiglio di Solventum (NYSE: SOLV) e Ampersand Biomedicines.
El T1D Fund, un fondo de inversión de impacto centrado en soluciones para la diabetes tipo 1, ha nombrado a Elizabeth Mily como CEO. Mily aporta más de 30 años de experiencia en roles en Bristol Myers Squibb, Goldman Sachs y Barclays, donde se especializó en estrategia corporativa y desarrollo empresarial.
En su nuevo cargo, Mily guiará la asignación de recursos del fondo y expandirá colaboraciones estratégicas para construir un ecosistema para nuevas terapias. También actuará como la principal embajadora pública del fondo, trabajando para aumentar la conciencia y la inversión en investigación e innovación sobre la T1D.
Antes de unirse al T1D Fund, Mily fue Vicepresidenta Ejecutiva de Estrategia y Desarrollo Empresarial en Bristol Myers Squibb, supervisando la estrategia de la empresa, innovación externa y desarrollo empresarial. Actualmente forma parte de la Junta de Solventum (NYSE: SOLV) y Ampersand Biomedicines.
T1D 기금은 1형 당뇨병 솔루션에 중점을 둔 임팩트 투자 기금으로, 엘리자베스 밀리를 CEO로 임명했습니다. 밀리는 브리스톨 마이어스 스큅(Bristol Myers Squibb), 골드만 삭스(Goldman Sachs), 바클레이즈(Barclays)에서 30년 이상의 경력을 쌓아왔으며, 기업 전략 및 비즈니스 개발 전문입니다.
신임 CEO로서 밀리는 기금의 자원 배치와 전략적 파트너십을 확대하여 새로운 치료법을 위한 생태계를 구축할 것입니다. 그녀는 기금을 대표하는 주요 대외 홍보대사로 활동하며, T1D 연구 및 혁신에 대한 인식과 투자를 증가시키기 위해 노력할 것입니다.
T1D 기금에 합류하기 전, 밀리는 브리스톨 마이어스 스큅에서 전략 및 비즈니스 개발 부사장으로 재직하며 회사의 전략, 외부 혁신 및 비즈니스 개발을 감독했습니다. 현재 솔벤트럼 (NYSE: SOLV) 및 앰퍼샌드 생명과학의 이사회에 재직 중입니다.
Le T1D Fund, un fonds d'investissement à impact axé sur les solutions pour le diabète de type 1, a nommé Elizabeth Mily comme PDG. Mily apporte plus de 30 ans d'expérience dans des rôles chez Bristol Myers Squibb, Goldman Sachs et Barclays, où elle s'est spécialisée dans la stratégie d'entreprise et le développement commercial.
Dans son nouveau rôle, Mily dirigera l'allocation des ressources du fonds et élargira les partenariats stratégiques pour construire un écosystème pour de nouvelles thérapies. Elle sera l'ambassadrice principale du fonds, travaillant à accroître la sensibilisation et les investissements dans la recherche et l'innovation sur le T1D.
Avant de rejoindre le T1D Fund, Mily a été vice-présidente exécutive de la stratégie et du développement commercial chez Bristol Myers Squibb, supervisant la stratégie de l'entreprise, l'innovation externe et le développement commercial. Elle siège actuellement au conseil d'administration de Solventum (NYSE: SOLV) et d'Ampersand Biomedicines.
Der T1D Fonds, ein Impact-Investmentfonds, der sich auf Lösungen für Typ-1-Diabetes konzentriert, hat Elizabeth Mily zur CEO ernannt. Mily bringt über 30 Jahre Erfahrung aus verschiedenen Positionen bei Bristol Myers Squibb, Goldman Sachs und Barclays mit, wo sie sich auf Unternehmensstrategie und Geschäftsentwicklung spezialisiert hat.
In ihrer neuen Rolle wird Mily die Ressourcenzuweisung des Fonds leiten und strategische Partnerschaften ausbauen, um ein Ökosystem für neue Therapien aufzubauen. Sie wird als Hauptbotschafterin des Fonds fungieren und daran arbeiten, das Bewusstsein und die Investitionen in die T1D-Forschung und -Innovation zu erhöhen.
Vor ihrem Eintritt in den T1D Fonds war Mily als Executive Vice President für Strategie und Geschäftsentwicklung bei Bristol Myers Squibb tätig, wo sie die Unternehmensstrategie, externe Innovation und Geschäftsentwicklung überwachte. Derzeit ist sie im Vorstand von Solventum (NYSE: SOLV) und Ampersand Biomedicines tätig.
- Appointment of seasoned executive with 30+ years of pharma and healthcare investment experience
- Strong strategic partnerships background with major biopharma companies
- Extensive experience in managing business development and external innovation
- Current board member of NYSE-listed Solventum (SOLV)
- None.
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy
Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker
"Elizabeth brings a bold strategic vision to the T1D Fund during an exciting period of our evolution. She is the ideal choice to lead the next chapter as we identify and invest in cutting-edge approaches for treating type 1 diabetes," said Tim Clark, Chair of the Board of Directors at the T1D Fund.
Mily joins the T1D Fund after most recently serving as Executive Vice President, Strategy & Business Development, at Bristol Myers Squibb, where she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company's broad equity investing portfolio. Previously, she held senior roles at Barclays, Thermo Fisher Scientific, and Goldman, Sachs & Co., where she led strategy and transactions for the healthcare, life sciences, and biopharma sectors. Mily currently serves on the Board of Solventum Corporation (NYSE: SOLV), where she sits on the Audit and Quality, Science & Technology Committees; she also serves on the Board of Ampersand Biomedicines, a private Flagship Pioneering portfolio company.
"The T1D Fund's unique position as an impact investor enables it to go beyond capital deployment to proactively work with biopharma to bring forward innovative therapies with the potential to translate to transformative cures," said Mily. "As someone who knows first-hand the serious impacts the disease has on individuals and their loved ones, I am eager to build upon the team's meaningful work and partnerships to propel treatments that can improve the lives of those with type 1 diabetes."
"Elizabeth's wealth of industry knowledge will be instrumental in the T1D Fund's ability to serve as a true biopharma partner—capitalizing on unique opportunities and directing market attention to develop treatments for patients with type 1 diabetes," said David Panzirer, Trustee of The Leona M. and Harry B. Helmsley Charitable Trust. "Leveraging its deep relationships with Helmsley Charitable Trust and Breakthrough T1D alongside Mily, the Fund is well-positioned to successfully drive a multitude of breakthroughs to market readiness."
About the T1D Fund: A Breakthrough T1D Venture, LLC
The T1D Fund is an impact investment fund accelerating life-changing solutions to treat, prevent, and ultimately cure type 1 diabetes (T1D). Launched in December 2016, it is the first scaled, mission-driven venture impact fund established to catalyze the development of T1D cure-oriented therapies through equity investments in partnership with additional sources of capital, including venture capital, corporations, and foundations. T1D Fund is managed by a dedicated team of investment professionals that invest in innovative approaches and novel mechanisms with curative potential in type 1 diabetes. Its focus is strategically aligned with Breakthrough T1D (formerly JDRF) and the Helmsley Charitable Trust, the leading global organizations funding T1D research and working to change the lives of those who are affected by T1D. Learn more at t1dfund.org. Follow the T1D Fund on Linkedin.
Media Contact
Lia Dangelico
lia.dangelico@deerfieldgroup.com
540-303-0180
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-t1d-fund-appoints-industry-veteran-elizabeth-mily-as-ceo-to-accelerate-development-of-type-1-diabetes-cures-through-impact-investing-302345016.html
SOURCE The T1D Fund
FAQ
What is Elizabeth Mily's background before joining T1D Fund as CEO?
What are Elizabeth Mily's responsibilities as T1D Fund's new CEO?
What boards does Elizabeth Mily currently serve on, including SOLV?
What is the T1D Fund's primary investment focus?
